Table 1 Demographic and Clinical Characteristics of the Study Sample
From: Estimation of healthcare‐related charges in women with BRCA mutations and breast cancer
Variables | BRCAm (n=134) | BRCAwt (n=682) | BRCAm vs. BRCAwt p-value |
|---|---|---|---|
Demographic Characteristics | |||
Age, Mean ± SD | 45.9 ± 9.4 | 47.1 ± 11.7 | 0.2575a |
Age, Median ± IQR | 45.0 ±12.9 | 45.9 ± 14.7 | 0.3853b |
Ethnicity | |||
Caucasian/ White | 116 (86.6%) | 598 (87.5%) | 0.9377c |
Non-White | 10 (7.5%) | 47 (6.9%) | |
Unknown | 8 (6.0%) | 37 (5.4%) | |
Plan Type | |||
Commercial | 93 (69.4%) | 426 (62.5%) | 0.1324c |
Medicare | 6 (4.5%) | 60 (8.8%) | |
Medicaid | 9 (6.7%) | 31 (4.6%) | |
Other/Unknown | 26 (19.4%) | 165 (24.2%) | |
Clinical Characteristics | |||
Stage at diagnosis | |||
I | 51 (38.1%) | 262 (38.4%) | 0.7387a |
II | 51 (38.1%) | 250 (36.7%) | |
III | 16 (11.9%) | 107 (15.7%) | |
IV | 9 (6.7%) | 34 (5.0%) | |
Unknown | 7 (5.2%) | 29 (4.3%) | |
Reeptor status | |||
ER+/PR+/HER2- | 53 (39.6%) | 349 (51.2%) | <0.0001a |
ER+/PR+/HER 2+ | 7 (5.2%) | 87 (12.8%) | |
TNBC | 38 (28.4%) | 81 (11.9%) | |
ER-/PR-/HER2+ | 8 (6.0%) | 40 (5.9%) | |
Other/Unknown | 28 (20.9%) | 125 (18.3%) | |
Tumor histologic grade | |||
1 | 7 (5.2%) | 115 (16.9%) | <0.0001a |
2 | 51 (38.1%) | 307 (45.0%) | |
3 | 70 (52.2%) | 218 (32.0%) | |
Unknown | 6 (4.5%) | 42 (6.2%) | |